<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844531</url>
  </required_header>
  <id_info>
    <org_study_id>1276.6</org_study_id>
    <secondary_id>2012-000082-20</secondary_id>
    <nct_id>NCT01844531</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets</brief_title>
  <official_title>Bioequivalence of Empagliflozin/Metformin (500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to establish bioequivalence of two fixed dose
      combination (FDC) tablets (containing medium dose empagliflozin/500 mg metformin [Test 1] and
      low dose empagliflozin/500 mg metformin [Test 2]) and of the single tablets (medium dose
      empagliflozin tablets + Glucophage® 500 mg tablet [Reference 1] and low dose empagliflozin
      tablet + Glucophage® 500 mg tablet [Reference 2]) when administered together after a high
      fat, high caloric meal.

      The assessment of safety and tolerability will be an additional objective of this trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0−∞ for Empagliflozin</measure>
    <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
    <description>AUC0−∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Empagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0−∞ for Metformin</measure>
    <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
    <description>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Empagliflozin</measure>
    <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
    <description>Cmax (maximum measured concentration of the analyte in plasma) for Empagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Metformin</measure>
    <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
    <description>Cmax (maximum measured concentration of the analyte in plasma) for Metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz for Empagliflozin</measure>
    <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
    <description>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz for Metformin</measure>
    <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
    <description>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Metformin</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>FDC empagliflozin dose 1 and metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fix dose combination tablet after intake of a high fat, high caloric meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin dose 1 + metformin tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single tablets after intake of a high fat, high caloric meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC empagliflozin dose 2 and metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fix dose combination tablet after intake of a high fat, high caloric meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin dose 2 + metformin tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single tablets after intake of a high fat, high caloric meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin</intervention_name>
    <description>single tablet empagliflozin</description>
    <arm_group_label>empagliflozin dose 1 + metformin tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin (Glucophage®)</intervention_name>
    <description>single tablet metformin</description>
    <arm_group_label>empagliflozin dose 1 + metformin tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin (Glucophage®)</intervention_name>
    <description>single tablet metformin</description>
    <arm_group_label>empagliflozin dose 2 + metformin tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin</intervention_name>
    <description>single tablet empagliflozin</description>
    <arm_group_label>empagliflozin dose 2 + metformin tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin and metformin</intervention_name>
    <description>FDC tablet empagliflozin and metformin</description>
    <arm_group_label>FDC empagliflozin dose 1 and metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin and metformin</intervention_name>
    <description>FDC tablet empagliflozin and metformin</description>
    <arm_group_label>FDC empagliflozin dose 2 and metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male and female subjects

          2. Subjects must be able to understand and comply with study requirements

          3. Age 18 to 50 years

          4. Body mass index (BMI) 18.5 to 29.9 kg/m2

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1276.6.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <results_first_submitted>June 26, 2015</results_first_submitted>
  <results_first_submitted_qc>June 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2015</results_first_posted>
  <last_update_submitted>June 26, 2015</last_update_submitted>
  <last_update_submitted_qc>June 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FDC Empa12.5/ Empa12.5+Met500/ FDC Empa5/ Empa5+Met500</title>
          <description>Participants first received Treatment T1 (12.5 mg empagliflozin/500 mg metformin Fixed Dose Combination (FDC)). After a washout phase of at least 5 days, they then received Treatment R1 (12.5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T2 (5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R2 (5 mg empagliflozin and 500 mg metformin, single tablets). Oral administration.</description>
        </group>
        <group group_id="P2">
          <title>Empa12.5+Met500/ FDC Empa12.5/ Empa5+Met500/ FDC Empa5</title>
          <description>Participants first received Treatment R1 (12.5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T1 (12.5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R2 (5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T2 (5 mg empagliflozin/500 mg metformin FDC). Oral administration.</description>
        </group>
        <group group_id="P3">
          <title>FDC Empa5/ Empa5+Met500/ FDC Empa12.5/ Empa12.5+Met500</title>
          <description>Participants first received Treatment T2 (5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R2 (5 mg empagliflozin and 500 mg metformin, single tablets)Treatment T1 (12.5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R1 (12.5 mg empagliflozin and 500 mg metformin, single tablets). Oral administration.</description>
        </group>
        <group group_id="P4">
          <title>Empa5+Met500/ FDC Empa5/ Empa12.5+Met500/ FDC Empa12.5</title>
          <description>Participants first received Treatment R2 (5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T2 (5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R1 (12.5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T1 (12.5 mg empagliflozin/500 mg metformin FDC). Oral administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set, included all subjects that entered the study and had taken at least 1 dose of trial medication.</population>
      <group_list>
        <group group_id="B1">
          <title>FDC Empa12.5/ Empa12.5+Met500/ FDC Empa5/ Empa5+Met500</title>
          <description>Participants first received Treatment T1 (12.5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R1 (12.5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T2 (5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R2 (5 mg empagliflozin and 500 mg metformin, single tablets).
Oral administration.</description>
        </group>
        <group group_id="B2">
          <title>Empa12.5+Met500/ FDC Empa12.5/ Empa5+Met500/ FDC Empa5</title>
          <description>Participants first received Treatment R1 (12.5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T1 (12.5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R2 (5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T2 (5 mg empagliflozin/500 mg metformin FDC).
Oral administration.</description>
        </group>
        <group group_id="B3">
          <title>FDC Empa5/ Empa5+Met500/ FDC Empa12.5/ Empa12.5+Met500</title>
          <description>Participants first received Treatment T2 (5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R2 (5 mg empagliflozin and 500 mg metformin, single tablets)Treatment T1 (12.5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R1 (12.5 mg empagliflozin and 500 mg metformin, single tablets). Oral administration.</description>
        </group>
        <group group_id="B4">
          <title>Empa5+Met500/ FDC Empa5/ Empa12.5+Met500/ FDC Empa12.5</title>
          <description>Participants first received Treatment R2 (5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T2 (5 mg empagliflozin/500 mg metformin FDC). After a washout phase of at least 5 days, they then received Treatment R1 (12.5 mg empagliflozin and 500 mg metformin, single tablets). After a washout phase of at least 5 days, they then received Treatment T1 (12.5 mg empagliflozin/500 mg metformin FDC). Oral administration.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="8.6"/>
                    <measurement group_id="B2" value="30.8" spread="7.6"/>
                    <measurement group_id="B3" value="35.8" spread="10.5"/>
                    <measurement group_id="B4" value="37.5" spread="9.0"/>
                    <measurement group_id="B5" value="35.6" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0−∞ for Empagliflozin</title>
        <description>AUC0−∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Empagliflozin</description>
        <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
        <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
        <group_list>
          <group group_id="O1">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>12.5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O2">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>12.5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
          <group group_id="O3">
            <title>5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O4">
            <title>5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0−∞ for Empagliflozin</title>
          <description>AUC0−∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Empagliflozin</description>
          <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2780" spread="16.1"/>
                    <measurement group_id="O2" value="2870" spread="17.3"/>
                    <measurement group_id="O3" value="1110" spread="15.7"/>
                    <measurement group_id="O4" value="1070" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa12.5 : Empa12.5 + Met500, PK set AUCinfpred [nmol*h/L] for EMPAGLIFLOZIN (PLASMA EDTA). The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>Model included effects:sequence;subjects within sequences;period and treatment with subjects within sequences as random effect.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>97.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.529</ci_lower_limit>
            <ci_upper_limit>102.520</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa12.5 : Empa12.5 + Met500, PK set AUCinfpred [nmol*h/L] for EMPAGLIFLOZIN (PLASMA EDTA). The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Model included effects:sequence;subjects within sequences;period and treatment with all effects as fixed.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>98.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.57</ci_lower_limit>
            <ci_upper_limit>102.65</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa5 : Empa5 + Met500 , PK set AUCinfpred [nmol*h/L] for EMPAGLIFLOZIN (PLASMA EDTA). The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>Model included effects:sequence;subjects within sequences;period and treatment with subjects within sequences as random effect.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>102.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.077</ci_lower_limit>
            <ci_upper_limit>106.633</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa5 (T2) : Empa5 + Met500 (R2), PK set AUCinfpred [nmol*h/L] for EMPAGLIFLOZIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>102.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.78</ci_lower_limit>
            <ci_upper_limit>106.36</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0−∞ for Metformin</title>
        <description>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin</description>
        <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
        <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
        <group_list>
          <group group_id="O1">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>12.5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O2">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>12.5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
          <group group_id="O3">
            <title>5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O4">
            <title>5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0−∞ for Metformin</title>
          <description>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin</description>
          <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5590" spread="19.0"/>
                    <measurement group_id="O2" value="5820" spread="21.8"/>
                    <measurement group_id="O3" value="5960" spread="18.0"/>
                    <measurement group_id="O4" value="6190" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa12.5 : Empa12.5 + Met500, PK set AUCinfpred [ng*h/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>96.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.542</ci_lower_limit>
            <ci_upper_limit>104.628</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa12.5 (T1) : Empa12.5 + Met500 (R1), PK set AUCinfpred [ng*h/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>97.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.41</ci_lower_limit>
            <ci_upper_limit>105.68</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa5 : Empa5 + Met500, PK set AUCinfpred [ng*h/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>96.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.772</ci_lower_limit>
            <ci_upper_limit>102.093</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa5 : Empa5 + Met500, PK set AUCinfpred [ng*h/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>96.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.79</ci_lower_limit>
            <ci_upper_limit>102.32</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz for Empagliflozin</title>
        <description>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Empagliflozin</description>
        <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
        <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
        <group_list>
          <group group_id="O1">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>12.5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O2">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>12.5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
          <group group_id="O3">
            <title>5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O4">
            <title>5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz for Empagliflozin</title>
          <description>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Empagliflozin</description>
          <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2740" spread="16.3"/>
                    <measurement group_id="O2" value="2830" spread="17.3"/>
                    <measurement group_id="O3" value="1080" spread="15.7"/>
                    <measurement group_id="O4" value="1040" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa12.5 : Empa12.5 + Met500, PK set AUClast [nmol*h/L] for EMPAGLIFLOZIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>98.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.530</ci_lower_limit>
            <ci_upper_limit>102.686</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa12.5 : Empa12.5 + Met500, PK set AUClast [nmol*h/L] for EMPAGLIFLOZIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>98.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.55</ci_lower_limit>
            <ci_upper_limit>102.81</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa5 : Empa5 + Met500, PK set AUClast [nmol*h/L] for EMPAGLIFLOZIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>102.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.146</ci_lower_limit>
            <ci_upper_limit>106.522</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa5 : Empa5 + Met500, PK set AUClast [nmol*h/L] for EMPAGLIFLOZIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>102.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.85</ci_lower_limit>
            <ci_upper_limit>106.25</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Empagliflozin</title>
        <description>Cmax (maximum measured concentration of the analyte in plasma) for Empagliflozin</description>
        <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
        <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
        <group_list>
          <group group_id="O1">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>12.5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O2">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>12.5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
          <group group_id="O3">
            <title>5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O4">
            <title>5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Empagliflozin</title>
          <description>Cmax (maximum measured concentration of the analyte in plasma) for Empagliflozin</description>
          <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294" spread="23.7"/>
                    <measurement group_id="O2" value="282" spread="27.4"/>
                    <measurement group_id="O3" value="109" spread="22.8"/>
                    <measurement group_id="O4" value="106" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa12.5 : Empa12.5 + Met500, PK set Cmax [nmol/L] for EMPAGLIFLOZIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>104.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.882</ci_lower_limit>
            <ci_upper_limit>109.555</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa12.5 : Empa12.5 + Met500, PK set Cmax [nmol/L] for EMPAGLIFLOZIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>104.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.76</ci_lower_limit>
            <ci_upper_limit>109.53</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa5 : Empa5 + Met500, PK set Cmax [nmol/L] for EMPAGLIFLOZIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>102.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.917</ci_lower_limit>
            <ci_upper_limit>108.258</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa5 : Empa5 + Met500, PK set Cmax [nmol/L] for EMPAGLIFLOZIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>102.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.72</ci_lower_limit>
            <ci_upper_limit>108.14</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Metformin</title>
        <description>Cmax (maximum measured concentration of the analyte in plasma) for Metformin</description>
        <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
        <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
        <group_list>
          <group group_id="O1">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>12.5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O2">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>12.5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
          <group group_id="O3">
            <title>5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O4">
            <title>5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Metformin</title>
          <description>Cmax (maximum measured concentration of the analyte in plasma) for Metformin</description>
          <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="686" spread="14.1"/>
                    <measurement group_id="O2" value="718" spread="19.7"/>
                    <measurement group_id="O3" value="693" spread="12.8"/>
                    <measurement group_id="O4" value="743" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa12.5 : Empa12.5 + Met500, PK set Cmax [ng/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>94.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.056</ci_lower_limit>
            <ci_upper_limit>100.819</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa12.5 : Empa12.5 + Met500, PK set Cmax [ng/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>94.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.64</ci_lower_limit>
            <ci_upper_limit>100.54</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa5 : Empa5 + Met500, PK set Cmax [ng/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>93.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.006</ci_lower_limit>
            <ci_upper_limit>100.034</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa5 : Empa5 + Met500, PK set Cmax [ng/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>93.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.94</ci_lower_limit>
            <ci_upper_limit>100.43</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz for Metformin</title>
        <description>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Metformin</description>
        <time_frame>1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake</time_frame>
        <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
        <group_list>
          <group group_id="O1">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>12.5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O2">
            <title>12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>12.5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
          <group group_id="O3">
            <title>5 mg Empagliflozin and 500 mg Metformin as FDC</title>
            <description>5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
          </group>
          <group group_id="O4">
            <title>5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
            <description>5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz for Metformin</title>
          <description>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Metformin</description>
          <population>Pharmacokinetics set (PKS) included all treated subjects with at least 1 evaluable observation for at least 1 primary pharmacokinetic endpoint without important protocol violations relevant to the statistical evaluation of pharmacokinetics who had not taken any restricted medication and had not experienced emesis before or at 2 times median tmax</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5480" spread="18.9"/>
                    <measurement group_id="O2" value="5720" spread="21.2"/>
                    <measurement group_id="O3" value="5820" spread="17.7"/>
                    <measurement group_id="O4" value="6110" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa12.5 : Empa12.5 + Met500, PK set AUClast [ng*h/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>95.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.000</ci_lower_limit>
            <ci_upper_limit>104.256</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa12.5 : Empa12.5 + Met500, PK set AUClast [ng*h/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>96.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.78</ci_lower_limit>
            <ci_upper_limit>105.41</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability comparison FDC Empa5 : Empa5 + Met500, PK set AUClast [ng*h/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>95.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.199</ci_lower_limit>
            <ci_upper_limit>100.934</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Adjusted by−treatment geometric means and relative bioavailability − analysis with fixed effects for all terms comparison FDC Empa5 : Empa5 + Met500, PK set AUClast [ng*h/mL] for METFORMIN (PLASMA EDTA)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted gMean ratio FDC/single tablets</param_type>
            <param_value>96.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.28</ci_lower_limit>
            <ci_upper_limit>101.19</ci_upper_limit>
            <estimate_desc>*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation [%].</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study drug administration of 1 treatment period until study drug administration in the next treatment period or date of trial completion plus 1 day, up to 8 days (and up to 16 days for one subject only)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>12.5 mg Empagliflozin and 500 mg Metformin as FDC</title>
          <description>12.5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
        </group>
        <group group_id="E2">
          <title>12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
          <description>12.5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
        </group>
        <group group_id="E3">
          <title>5 mg Empagliflozin and 500 mg Metformin as FDC</title>
          <description>5 mg empagliflozin/500 mg metformin as Fixed Dose Combination, oral administration</description>
        </group>
        <group group_id="E4">
          <title>5 mg Empagliflozin and 500 mg Metformin as Single Tablets</title>
          <description>5 mg empagliflozin and 500 mg metformin as single tablets, oral administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

